Your session is about to expire
← Back to Search
CAR-T Therapy for Multiple Myeloma
Study Summary
This trial studies a new type of cancer therapy to treat relapsed and refractory multiple myeloma. It investigates the safety and effectiveness of the therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with POEMS syndrome.I have previously received genetically modified cell therapy, including BCMA CAR-T.I have previously received BCMA-targeted therapy.I have completed at least 3 treatment cycles for my condition.My condition is not multiple myeloma but another plasma cell disorder.My leukapheresis material is approved for use.My condition worsened within 2 months after my last treatment.I have had a stem cell transplant within the past 3 to 6 months.I am fully active or restricted in physically strenuous activity but can do light work.You have a disease that can be measured according to the study's guidelines.My cancer has spread to my brain or spinal cord.I have an active neurological autoimmune or inflammatory disorder.I am 18 years old or older.My heart, kidneys, liver, or blood are not functioning well.I've had 3+ treatments for my condition, including specific drugs, and my disease is still getting worse.
- Group 1: PHE885
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants being sought at this time for the clinical trial?
"The clinical trial is currently seeking volunteers, as indicated on the official website. The listing was originally posted in March of 2022 and updated last month (February 2023)."
What have been the results of assessments on PHE885's safety to patients?
"In light of the fact this is still a Phase 2 trial with limited data, our team has assigned PHE885 an assessment score of two; indicating that safety is supported to some degree but efficacy remains unproven."
What is the total number of participants in this experiment?
"Indeed, the clinical trial is indeed recruiting patients. According to its description on clinicaltrials.gov, which was originally published on March 7th 2022 and recently modified February 15th 2023, it aims to recruit 136 participants from two distinct health facilities."
What is the purpose of this experimental process?
"The primary goal of the trial, which will span two years, is to gauge overall response rate (ORR) as determined by an Independent Review Committee. Secondary objectives include measuring durability of minimal residual disease negativity, transgene PHE885 concentrations in peripheral blood and bone marrow over time via quantitative polymerase chain reaction testing and complete response rate according to International Myeloma Working Group criteria."
Share this study with friends
Copy Link
Messenger